IMA, US45175G2075

ImageneBio grants 90,775 units: ImageneBio stock sits 55.71 percent below its high

Published on 10/16/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright kept a USD 28.00 target on October 1, 2026. ImageneBio stock sits 55.71 percent below its high before November 11, 2026 results.

Grant details and key dates

ImageneBio reported 90,775 restricted stock units and 32,725 options on October 2, 2026.
H.C. Wainwright maintained a USD 28.00 target on October 1, 2026.
The next quarterly report is scheduled for November 11, 2026.

IMA, US45175G2075, Illustration mit AI erstellt.

ImageneBio (ISIN US45175G2075) reported on October 2, 2026, that it granted 90,775 restricted stock units and 32,725 non-qualified stock options to three newly hired employees, according to BioSpace. The grants were approved on September 30, 2026, and give investors a concrete marker for the companys hiring plans.

Three grants, four-year vesting

The awards were structured under ImageneBios 2025 Equity Inducement Plan. Each option carries an exercise price of USD 4.58, the closing price of the common stock on September 30, 2026, while the awards vest over four years, BioSpace reported. The near-term investor question is whether the additional staff supports the Phase 2b study of olevaprubart, ImageneBios lead anti-OX40 antibody program.

Chronology adds operating context

On September 14, 2026, ImageneBio was scheduled to present at the H.C. Wainwright conference at 3:30 p.m. EDT, according to the company investor page. On September 30, 2026, the company listed two EADV conference posters with file sizes of 1.7 MB and 1 MB. On October 2, 2026, it reported the 90,775 RSUs and 32,725 options through ImageneBio and BioSpace.

What does the grant change?

The immediate effect is a larger potential share count, with 32,725 options and 90,775 RSUs tied to three hires. The four-year vesting schedule spreads the awards over time rather than creating a one-day cash expense for the entire package. The company is conducting a Phase 2b trial in moderate-to-severe atopic dermatitis, according to its investor materials.

Analyst target and next report

On October 1, 2026, H.C. Wainwright maintained a Buy rating and a USD 28.00 price target, as reported by Markets Insider. The same report said the latest quarterly GAAP net loss was USD 10.18 million for the quarter ended June 30, 2026, compared with USD 2.77 million a year earlier. The next quarterly report is scheduled for November 11, 2026, according to Investing.com.

Stock remains near its yearly low

ImageneBio was last at USD 4.03 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. Its market capitalization was USD 45.7 million, while the 52-week range was USD 3.90 to USD 9.10 as of October 16, 2026. The last price stood 55.71 percent below the 52-week high.